EFTA02122172.pdf

To: From: Sent Tue 11/12/2013 11:08:35 PM Subject Re: Mezzanine financing sought before IPO by Epiphany Biosciences — let's talk Thanks David. Will pass along and ask if Jeffrey would like to set up a call Sent from my iPhone On Nov 12, 2013, at 5:57 PM, David Grosof <grosof@sloan.mit.edu> wrote: > Hi, Lesley, > As per phone message on your line, I've attached a slide deck, with many industry abbreviations/jargon, for Epiphany Biosciences. The CEO Fred Volinsky spoke with Jeffrey back in 2006-7, shortly after I did some consulting for it. I'd like Jeffrey to consider investing 250K-300K on mezzanine terms that I can sketch out but can and ought to be discussed in depth with Fred Volinsky. I think it's a promising deal, and I'm introducing it to another associate as well. > I'll add that the lead compound that constitutes the prime asset of Epiphany is one I assessed with the founders in 2006, so I'm not surprised it's progressed clinically or commercially. > There are others being offered this mezzanine opportunity and indications of interest by others might be happening in the next few business days. (Fred's an aggressive salesman but I've never caught him blowing smoke.) > I'm reachable after 8:30 am PST (11:30 EST) Wednesday, tomorrow. > I'd like to emphasize that I'm a huge fan of scheduling a call, if only 20 minutes in advance, rather than get called out of the blue while I'm, say, pumping a bicycle tire, working out, standing in line at a drug store, etc. > Thanks for your attention... > Cheers, > David landline mobile > David Grosof • > * > <DRAFT_Epiphany_Overview_09JUL13_v31.ppt> EFTA_R1_00756732 EFTA02122172